Survivin mRNA antagonists using locked nucleic acid, potential for molecular cancer therapy.

Abstract

We have investigated the effects of different locked nucleic acid modified antisense mRNA antagonists against Survivin in a prostate cancer model. These mRNA antagonists were found to be potent inhibitors of Survivin expression at low nanomolar concentrations. Additionally there was a pronounced synergistic effect when combining the mRNA antagonists against Survivin with the chemotherapeutic Taxol. This effect was demonstrated at concentrations of antagonists far lower than any previously demonstrated, indicating the high potential of locked nucleic acid for therapeutic use. Further characterisations in vivo are ongoing.

• Authors: Niels Fisker, Majken Westergaard, Henrik Frydenlund Hansen, Jens Bo Hansen
• Journal: Nucleosides, nucleotides & nucleic acids (Nucleosides Nucleotides Nucleic Acids) Vol. 26 Issue 10-12 Pg. 1427-30 ( 2007) ISSN: 1525-7770 [Print] United States
• PMID: 18066798 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents
• BIRC5 protein, human
• Inhibitor of Apoptosis Proteins
• Microtubule-Associated Proteins
• Neoplasm Proteins
• Oligonucleotides
• RNA, Antisense
• RNA, Messenger
• Survivin
• locked nucleic acid

Topics

• Antineoplastic Agents (pharmacology, therapeutic use)
• Cell Line, Tumor
• Humans
• Inhibitor of Apoptosis Proteins
• Male
• Microtubule-Associated Proteins (antagonists & inhibitors)
• Neoplasm Proteins (antagonists & inhibitors)
• Oligonucleotides (chemistry)
• Prostatic Neoplasms (drug therapy)
• RNA, Antisense (chemistry, pharmacology, therapeutic use)
• RNA, Messenger (antagonists & inhibitors)
• Survivin